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ABSTRACT
Glioblastoma multiforme (GBM) often features a combination of tumour 
suppressor gene inactivation and multiple oncogene overactivation. The Axl 
receptor tyrosine kinase is found overexpressed in GBM and thought to contribute to 
invasiveness, chemoresistance and poor survival. Here, we have evaluated the effect 
of BGB324, a clinical candidate Axl-specific small molecule inhibitor, on the invasive 
behaviour of human GBM cells in vitro, as an indicator of its potential in GBM therapy 
and also to elucidate the role of Axl in GBM pathogenesis. 
Two cultured adult GBM cell lines, SNB-19 and UP007, were treated with Gas6 
and/or BGB324, and analysed in assays for survival, 3D colony growth, motility, 
migration and invasion. Western blot was used to detect protein expression and 
signal protein phosphorylation. In both cell lines, BGB324 inhibited specifically 
phosphorylation of Axl as well as Akt kinase further downstream. BGB324 also 
inhibited survival and proliferation of both cell lines in a concentration-dependent 
manner, as well as completely suppressing migration and invasion. Furthermore, 
our results indicate co-operative activation between the Axl and Tyro3 receptors, as 
well as ligand-independent Axl signalling, to take place in GBM cells. In conclusion, 
small molecule inhibitor-led targeting of Axl may be a promising therapy for GBM 
progression.
INTRODUCTION
The TAMs (Tyro3, Axl, MerTK) are a subfamily 
of receptor tyrosine kinases (RTKs) that share structural 
homology in their extracellular regions, comprising a 
pair of immunoglobulin-like domains followed by two 
fibronectin type III repeats. This is followed by the RTK 
family-wide possession of an intracellular tyrosine kinase 
domain. The natural ligands for the TAMs are the vitamin 
K-dependent proteins Gas6 (for all three receptors, with 
highest affinity for Axl) and Protein S (Tyro3 and MerTK 
only) [1-5]. 
Axl has been shown to mediate cell survival, 
proliferation, migration and adhesion [6], whilst all three 
receptors have been shown to play a role in immune cell 
differentiation and phagocytic clearance of apoptotic cells 
[4, 7-9]. In addition, Tyro3 has been shown to exert neuro-
protective functions in the central nervous system (CNS), 
where it is the most prominently expressed TAM [10, 11]. 
Additionally, Gas6, Protein S and Axl have been shown to 
be expressed by stem cells in the subventricular zone and 
to regulate their proliferation, survival and differentiation 
[12, 13]. Axl/Gas6 signalling also protects axon integrity 
[14]. This variety of roles indicates diversity in the 
signalling pathways activated by the TAMs in normal 
cellular homeostasis. 
Aberrant TAM signalling through e.g. 
overexpression has been observed in multiple cancers, 
including gliomas [6]. Gliomas are the most common 
form of brain cancer and are classified morphologically 
according to the glial cell type from which they are 
derived. In addition to the morphological classification, 
they are usually distinguished by the WHO grading 
system [15]. Lower grade tumours (grade I and grade 
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II) are well differentiated and resemble normal tissue, 
whereas higher grade tumours (grade III and grade IV) 
are anaplastic and display high cell atypia and mitotic 
activity [15]. Glioblastoma multiforme (GBM) is a grade 
IV glioma and is highly heterogeneous and invasive 
in nature. The current standard treatment for gliomas 
consists of surgical tumour resection, radiotherapy and 
adjuvant temozolomide chemotherapy [16, 17]. The 
5-year survival rate for GBM patients is less than 5%, 
indicating the slow progress in therapy development and 
therefore the need for more effective treatments [18]. 
Recent studies have demonstrated overexpression of 
MerTK or Axl in astrocytic tumours of all grades, and co-
expression of MerTK and Axl in all high grade glioma 
tissue samples, relative to little or no expression in normal 
CNS [19, 20]. Experimental blockade of Axl signalling 
in cultured GBM cells resulted in decreased growth and 
invasive potential [21]. Axl expression, and resulting 
invasiveness of glioma cells, has been shown to be directly 
regulated by the transcriptional regulator EZH2 through 
a mechanism independent of histone methylation [22]. 
Additionally, glioma cells with elevated MerTK activation 
showed greater resistance to pro-apoptotic stimuli as well 
as increased invasive potential compared to cells with 
MerTK expression silenced [23, 24]. Together, these 
observations suggest the TAMs to be an attractive new 
target for GBM therapy. 
Novel, selective small molecule inhibitors (SMIs) 
of RTKs are increasingly being developed as promising 
new targeted molecular therapies for a variety of cancers. 
BGB324 (also known as R428) [(1-(6,7-dihydro-5H-
benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-((7-
pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-
2-yl)-1H-1,2,4-triazole-3,5-diamine)] is a highly selective 
SMI of Axl (out of 133 tyrosine and serine/threonine 
kinases tested) [25]. Treatment of mesenchymal carcinoma 
cells with BGB324 abolished cell invasion and increased 
chemosensitivity [26], whilst it nullified the tumorigenic 
effect of triple negative breast cancer as well as blocking 
their acquired resistance to erlotinib (anti-EGFR SMI). 
BGB324 is currently in Phase 1b clinical trials for acute 
myeloid leukaemia and non-small cell lung cancer, and 
has so far been shown to be safely tolerated in clinical 
safety studies in healthy volunteers at doses up to 1.5 g 
daily (http://www.bergenbio.com/BGB324). Additionally, 
in breast cancer mouse models, twice daily dosing of 
25, 50, and 100 mg/kg BGB324 resulted in mouse 
plasma concentrations of 2.4, 6.8, and 9.0 µM BGB324 
respectively [25]. 
Here, we report our observations from a 
comprehensive study of the cell biological and signalling 
effects of BGB324 on two distinct patient-derived GBM 
cell lines. We demonstrate that as an SMI, BGB324 
selectively inhibits Axl-mediated growth, motility, 
migration and invasion of GBM cells, as effectively 
as when Axl is genetically knocked down. Therefore, 
this study reveals Axl as an important mediator of 
gliomagenesis, and indicates that specific targeting of 
Axl with a highly selective SMI represents a new and 
promising therapeutic avenue for GBM patients. 
RESULTS
The TAMs are overexpressed in GBM cells
We first conducted an expression screen of all 
TAMs in different human brain cell types, as well as 
the GBM cell lines involved in this study (Figure 1). 
In terms of protein expression, Axl and MerTK were 
the more prominently expressed TAMs in human brain 
microvascular endothelial cells (hCMEC/D3), while 
only Axl and Tyro3 were expressed in human cerebellar 
astrocytes (HA-c) (Figure 1A). Both GBM cell lines 
SNB-19 and UP007 showed strong expression of Axl and 
Tyro3 but negligible expression of MerTK. Quantitative 
real-time PCR analysis also confirmed our western blot 
results with similar expression patterns for each TAM 
gene (Figure 1B). Interestingly, both MerTK and Tyro3 
showed high expression in whole normal human brain 
relative to the individual cell types, WHILST the opposite 
was true for Axl. Additionally, Gas6 mRNA was found 
to be most prominently expressed in normal human 
astrocytes and the UP007 cell line. Furthermore, from 
immunohistochemical staining for Axl in a GBM tissue 
array, we detected aberrant expression of Axl protein in a 
subset of GBM tumours (Supplementary Figure 1); this is 
in keeping with gene expression profiling studies showing 
Axl upregulation in brain tumours [27]. 
Gas6 activates Axl signalling in GBM cells
Gas6 is the principal ligand for all three TAM 
receptors and has also been found to be overexpressed in 
glioma [20]. Exogenous Gas6 stimulated phosphorylation 
of Axl in SNB-19 cells but failed to do the same in UP007 
cells (Figure 2A and Supplementary Figure 2A). In 
addition, Gas6 did not stimulate Tyro3 phosphorylation in 
either cell line (Figure 2B and Supplementary Figure 2B). 
However, Gas6 rapidly induced downstream intracellular 
Akt phosphorylation in both cell lines by approximately 
two-fold (Figures 2C and Supplementary Figure 2C). 
BGB324 selectively inhibits Axl activity and 
downstream signalling in GBM cells
BGB324 is an Axl-selective SMI, with a 15-fold 
greater inhibitory efficacy versus the other TAMs in 
biochemical assays [25]. In order to initially evaluate 
the specificity of BGB324, we tested its effect on the 
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activation of EGFR in the two GBM cell lines. EGFR 
in cells was rapidly activated by EGF stimulation within 
15min, an effect that was abolished by the EGFR-specific 
SMI gefitinib (Figure 3). However, pre-incubation with 
BGB324 had no effect on the EGFR activation by EGF 
(Figure 3). 
We then evaluated the effect of BGB324 on Gas6-
stimulated activity of Axl and Tyro3 in the GBM cell lines. 
Pre-incubation with BGB324 did not inhibit Gas6-induced 
Axl phosphorylation in SNB-19 cells at up to 10 µM. 
However, in UP007 cells, BGB324 markedly inhibited 
Axl phosphorylation (which was Gas6-independent) 
at 10 µM to below baseline levels (Figure 4A and 
Supplementary Figure 3A). BGB324 had no effect on 
Tyro3 phosphorylation levels in SNB-19 cells, whereas 
it showed a trend towards significance in inhibition in 
UP007 cells (Figure 4B and Supplementary Figure 3B). 
At 100 µM, BGB324 was toxic to all cells, as reflected 
by the absence of a band for β-actin in the western blots. 
Next, the effect of BGB324 on activation of 
downstream signalling was investigated in the GBM 
cells. BGB324 pre-treatment significantly inhibited Akt 
phosphorylation in a concentration-dependent manner in 
both cell lines, independently of Gas6 stimulation (Figure 
4C and Supplementary Figure 3C). Therefore, the Akt 
signalling pathway appears to emanate from Axl activation 
in both GBM cell lines. In contrast to Akt signalling, 
BGB324 had no effect on NF-κB pathway activation in 
both GBM cell lines (data not shown), indicating a lack 
of involvement of this pathway in Axl signalling in the 
GBM cells. 
Figure 1: A. Western blot screen of TAM receptors in protein extracts from a panel of human brain cell cultures: microvascular endothelial 
cells (hCMEC/D3), astrocytes (HA-c) and two GBM cell lines, SNB-19 and UP007. B. Quantitative PCR analysis of mRNA expression 
of the genes for Axl, MerTK, Tyro3 and Gas6 in extracts from human whole brain (WB), endothelial cells, astrocytes, SNB-19 and UP007 
cells. 
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Figure 2: Effect of Gas6 stimulation on TAM phosphorylation and signalling in GBM cells. Western blot showing time-
course of Axl phosphorylation by Gas6 (400 ng/ml) in SNB-19 and UP007 cells (A. n = 5 blots for both cell lines), of Tyro3 phosphorylation 
in SNB-19 and UP007 cells (B. n = 3 blots for both cell lines), and of pAkt levels C. in SNB-19 (n = 3 blots) and UP007 (n = 4 blots) cells. 
Data are mean±SEM protein expression normalised against loading control protein; *p < 0.05 and ns, not significant, versus time 0. 
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BGB324 inhibits GBM cell growth and colony 
formation
Having observed that BGB324 robustly inhibited 
Axl signalling in the GBM cells, we investigated the 
effect of BGB324 on cell growth and survival using both 
short-term and long-term cell-based assays. In short-term 
experiments (MTS assay after 72h), BGB324 significantly 
reduced viable cell number in both GBM cell lines in a 
concentration-dependent manner, with a slightly greater 
potency in UP007 cells (IC50 1 µM) compared to SNB-19 
cells (IC50 2.5 µM) (Figure 5A). Additionally, no significant 
increase in the number of apoptotic or necrotic cells was 
observed in both cell lines following 24h treatment with 
IC50 and double-IC50 concentrations of BGB324 (Figure 
5B). In long-term cell growth experiments in 3D (soft agar 
assays), BGB324 significantly reduced colony formation 
at 0.75 µM in UP007 cells, and inhibition of SNB-19 
colony formation was apparent at 2 µM of BGB324, with 
complete inhibition of colony growth without cell death 
achieved at 10 µM BGB324 (Figure 6). 
Temozolomide (TMZ) is a chemotherapeutic 
adjuvant to radiotherapy and is currently the only mildly 
successful chemotherapeutic agent for GBM, extending 
median survival by 3-4 months [16]. Therefore, we 
investigated a possible combinatorial effect of BGB324 
and TMZ in GBM cells. Treatment with TMZ resulted 
in concentration-dependent decreases in viability of both 
UP007 and SNB-19 cells (Figure 7). In addition, the 
inhibitory effect of BGB324 at 1 µM was significantly 
enhanced by co-incubation with 10 µM of TMZ, versus 
either agent alone. Also, combinations at 50 µM TMZ did 
not show a significantly increased effect in the presence of 
BGB324, possibly due to the increased toxicity of TMZ 
at such a high concentration. However, all concentrations 
of BGB324 exhibited enhanced inhibitory effects when 
combined with sub-toxic doses 10 µM and 25 µM of 
TMZ. 
BGB324 inhibits cell migration, motility and 
invasion in GBM cells
One of the biggest challenges in GBM treatment is 
the highly invasive nature of the tumours, which leads to 
multiple relapses. We therefore tested the effectiveness 
of BGB324 against the migration, motility and 
invasive capacity of the GBM cells. BGB324 inhibited 
cell migration in both SNB-19 and UP007 cells in a 
concentration-dependent manner (Figure 8A). Moreover, 
cell tracking experiments revealed that sub-IC50 doses 
of BGB324 profoundly inhibited the motility of cells in 
both lines, affecting both average velocity of movement 
and total distance travelled (Figure 8B). This indicates 
that BGB324 can effectively block cell motility at doses 
below those that can cause cell death. Furthermore, Axl 
inhibition with BGB324 abolished invasion by both GBM 
Figure 3: Western blot of EGFR phosphorylation by EGF in SNB-19 and UP007 cells, and influence of gefitinib and 
BGB324 on this. Data are mean±SEM (n = 3 separate experiments);**p < 0.01, *p < 0.05, ns, not significant, for comparisons indicated.
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Figure 4: Comparative efficacies of BGB324 for inhibition of Axl, Tyro3 and Akt phosphorylation in GBM cells. Western 
blots showing inhibition by BGB324 (0.1–100 µM) of phosphorylation of Axl A, Tyro3 B. and Akt kinase downstream C. stimulated by 
Gas6 (400ng/ml) in SNB-19 and UP007 cells. Data are mean ±SEM (n = 3 separate experiments);**p < 0.01, *p < 0.05, ns, not significant, 
for comparisons indicated. 
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cell lines through extracellular matrix that was stimulated 
with the glioma cell chemoattractant PDGF-AA (Figure 
8C). Therefore, BGB324 inhibits migration, motility and 
invasion of glioblastoma cells in vitro, which all contribute 
to the aggressive clinical features of GBM. 
DISCUSSION
GBM is the most common type of primary 
malignant brain tumour in adults and is highly 
heterogeneous and aggressive, with most patients facing 
only a year of survival [28]. It is this heterogeneous and 
Figure 5: Comparative efficacies of BGB324 for inhibition of GBM cell growth and effect on cell viability. A. MTS 
assay showing concentration-response effect of BGB324 on growth/viability of SNB-19 and UP007 cells. IC50 values were calculated 
from % inhibition vs log BGB324 concentration curves. B. Representative propidium iodide (PI) vs Annexin V fluorescence intensity in 
SNB-19 cells treated with vehicle, 2.5 µM and 5 µM BGB324. Quadrants and markers in the displayed plots were used to demarcate the 
various cell populations (top panel). Quantified, comparative cell counts (%) are shown for healthy, apoptotic and necrotic cells following 
24h BGB324 treatment of SNB-19 and UP007 cells (bottom panel). Data are mean±SEM (n = 3 separate experiments); ns, not significant 
versus untreated. 
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Figure 6: Effect of BGB324 on long-term growth of GBM cell colonies in 3D. Representative micrographs of SNB-19 colonies 
in soft agar at 1.5x magnification (above; i and ii) and 15x magnification (below; iii and iv) untreated (left) or treated with 10 µM BGB324 
(right). Histograms show average colony counts of 5 different fields per treatment for SNB-19 and UP007. Data are mean ±SEM (n = 3 
separate experiments); ****p < 0.0001 versus untreated. 
Figure 7: Effect of BGB324 on GBM cell growth in combination with Temozolomide (TMZ). MTS assay showing cell 
growth/survival of SNB-19 and UP007 cells treated with varying concentrations of TMZ alone or in combination with BGB324. Data are 
mean±SEM (n = 3 separate experiments); ****p < 0.0001, ***p < 0.001 versus untreated (UT). # indicates significance when compared 
to 10 µM of TMZ. 
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invasive character to GBM that renders conventional 
treatments ineffective. Despite intense investigation in 
the last decade, our understanding of the pathogenesis 
of these tumours still remains limited. It is thus of great 
importance to find new targeted therapies that will increase 
survival rates and quality of life for cancer patients. 
The TAMs have recently been associated with glioma 
pathophysiology, and therefore have emerged as attractive 
novel therapeutic targets for brain tumours as part of 
individualised treatment approaches. Therefore, SMIs 
such as the highly selective Axl inhibitor BGB324 could 
be more effective than the currently available treatments. 
Figure 8: Effect of BGB324 on GBM cell migration, motility and matrix invasion. A. Representative images from scratch 
wound assay for SNB-19 cells at 0 and 21 h (scale bar = 390 µm) followed by graphical representation of migration rate (area change per 
h) for SNB-19 and UP007 cells treated with varying concentrations of BGB324. B. Cell tracking experiments yielded data for average total 
distance travelled and average velocity for SNB-19 and UP007 cells following treatment with BGB324. C. Invasion assay for SNB-19 (n = 
3) and UP007 (n = 4) cells following treatment with BGB324 using PDGF-AA as chemoattractant. Data are mean ±SEM (n = 3 independent 
experiments); ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05 compared to untreated (UT) or as indicated. 
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The present study is the first to assess the effectiveness of 
an Axl-specific SMI on human GBM cells and on two cell 
lines with different characteristics. 
In agreement with previous studies, we have shown 
that Axl is overexpressed in both GBM cell lines used 
in this study [20], relative to its normal expression level 
in human astrocytes. Moreover, we also observed an 
overexpression of Tyro3 in both GBM cell lines, whereas 
MerTK was found to be expressed clearly only in brain 
microvascular endothelial cells. This expression profile 
of the TAMs is consistent with previous studies [6]. In 
particular, the observation that, in normal tissue, Tyro3 is 
prominently expressed in the brain but not in astrocytes or 
endothelium by exclusion suggests its expression either in 
neuronal cells or other glial cell types, or both. 
Gas6 is the common ligand for the TAM receptors, 
with in vitro studies demonstrating a higher affinity for 
Axl and Tyro3 than MerTK [29]. Using two GBM cell 
lines with a basal level of Axl activity, we observed 
that Gas6 activates Axl and Axl-associated signalling in 
SNB-19 cells but also that Axl signalling appeared to be 
Gas6-independent in the UP007 cell line. Gas6 did not 
stimulate Tyro3 phosphorylation above the basal levels 
apparent in either cell line. However, as MerTK was not 
investigated in this study, and Gas6 stimulated Akt and 
cell invasion in both cell lines, which cannot be explained 
by activation of Axl or Tyro3 in the UP007 cell line, these 
observations indicate a different route of stimulation by 
Gas6 in the GBM cells. It is conceivable however that 
Gas6 overexpression in GBM [20] can stimulate other 
TAMs in a paracrine manner or instead to supress an 
anti-tumour immune response. Furthermore, inhibition of 
Akt was observed in both cell lines following treatment 
with BGB324 even in the presence of Gas6, indicating 
that BGB324 is effective in inhibiting basal Axl activity 
and downstream signalling in a dose-dependent manner, 
irrespective of the ligand.
We investigated the effect of Axl inhibition with 
BGB324 on short-term growth/survival of GBM cells as 
well as long-term colony formation. BGB324 inhibited 
cell growth in both assays potently and in a concentration-
dependent manner. The two cell lines exhibited different 
responses, with the UP007 cell line being more susceptible 
to inhibition (IC50= 1 µM) than the SNB-19 cell line 
(IC50= 2.5 µM). The slightly greater resistance of SNB-
19 cells to BGB324 could possibly be due to a slight but 
sufficient expression of MerTK in that cell line, which 
UP007 completely lack, to compensate for inhibition of 
Axl. We probed the particular functional effect of BGB324 
on cell survival by apoptosis assays, and observed that 
treatment of cells with BGB324 did not significantly 
induce apoptosis or necrosis, thus demonstrating a clear 
retardation in cell growth at non-toxic concentrations. 
Therefore, this supports the potential of BGB324 as a 
targeted chemotherapeutic compound, in contrast to 
traditional chemotherapies. Furthermore, during cell 
tracking experiments, a hindrance of cell division was 
observed under the microscope in cells treated with 
BGB324, although the precise effect of the drug on the 
cell cycle requires investigation.
Activation of the serine/threonine kinase Akt was 
also blocked by BGB324 in both cell lines, even in the 
presence of Gas6. In accordance with previous data from 
a study using a dominant negative form of Axl in GBM 
cell lines [21], blocking Axl signalling with BGB324, 
in addition to inhibiting cell proliferation/survival, also 
reduced cell migration in a dose-dependent manner. The 
total distance travelled and the velocity of migration were 
reduced significantly at sub-IC50 concentrations for SNB-
19 and at the IC50 concentration for UP007 cells. Invasion 
was also reduced to basal levels after incubation with 
BGB324 following PDGF-AA stimulation in both cell 
lines, indicating that Axl mediates the invasive character 
of GBM cells in response to diverse humoral cues. Indeed, 
studies have shown that Axl mediates tumour invasion and 
chemoresistance through the activation of the PI3K/Akt 
pathway in breast cancer [30, 31] as well as ovarian cancer 
[32]. The BGB324 inhibition of GBM cell migration and 
invasion we observed could be the result of suppressed 
Akt signalling, although this requires further investigation. 
The TAM family members have been demonstrated 
to crosstalk with other receptors such as EGFR. Axl has 
been shown to increase EGFR-conferred chemoresistance 
in lung cancer [33], while it diversifies EGFR signalling 
and increased resistance to targeted therapy in triple 
negative breast cancer [34]. In our study we observed 
that inhibiting Axl activation by BGB324 did not affect 
activation of EGFR, supporting the specificity of BGB324 
for Axl as well as excluding the possibility of EGFR 
transactivation via Axl signalling. Moreover, neither did 
Gas6 stimulate further activation of EGFR. 
The possibility also exists for TAM family members 
to heterodimerise with each other. Previous studies have 
shown BGB324 to be more than 100-fold more selective 
for Axl than Tyro3 for kinase inhibition in vitro. In our 
study, BGB324 treatment of SNB-19 and UP007 cells 
resulted in a reduction of Tyro3 phosphorylation in 
UP007 cells but not in SNB-19 cells, indicating a possible 
heterodimerisation between Axl and Tyro3 to occur in 
UP007 cells. This could also account for the different 
sensitivities of the cell lines towards Gas6 stimulation and 
treatment with BGB324, and such a phenomenon warrants 
further investigation. 
The current treatment for GBM comprises surgical 
tumour resection followed by radiotherapy with adjuvant 
TMZ treatment, TMZ being an alkylating agent which 
acts by interfering with DNA replication, thus enhancing 
tumour cell death upon exposure to radiotherapy [17]. The 
ability of TMZ to cross the blood-brain barrier has made it 
a standard therapy for GBM, although patient survival is 
increased by only a few months. In recent years, the focus 
of TMZ combination with novel or current molecular 
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agents has been in the spotlight [17]. In the present study, 
we have observed a concerted interaction between TMZ 
and BGB324 in terms of their anti-growth effects on 
GBM cells. As the mechanisms for this interaction are 
not clear, a study with a larger number of concentration 
combinations is needed to explore this further. 
In conclusion, our data indicate that targeting Axl for 
inhibition by a specific SMI such as BGB324 has robust 
anti-tumour effects on GBM cells and could potentially 
be effective in restraining tumour invasion in vivo and, in 
combination with other agents, could effectively prolong 
glioma patient survival. Future studies will be needed to 
explore the anti-GBM tumour efficacy of Axl-selective 
SMIs such as BGB324, which has been established to 
be safe clinically and therefore may also be effective for 
combating highly malignant brain tumours that are driven 
by Axl. 
MATERIALS AND METHODS
Cell culture
The human GBM cell lines used in this study were 
UP007 (established in-house from GBM biopsy resected at 
King’s College Hospital, London under ethics permission 
LREC00-173/11/SC/0048) and SNB-19 (DSMZ German 
Brain Tumour Bank); both cell lines were authenticated in-
house as described previously [35] and were mycoplasma 
tested. Cells were normally cultured in complete medium, 
comprising Dulbecco’s Modified Eagle Medium (Fisher 
Scientific, Loughborough, UK) supplemented with 
10% foetal bovine serum (Lonza, Slough, UK), 2 mM 
L-glutamine (Life Technologies, Paisley, UK) and 1% 
penicillin/streptomycin (Fisher Scientific). Cells were 
routinely grown to confluence in a humidified incubator 
with 5% CO2 at 37
◦C and passaged through dissociation 
with trypsin/EDTA (Lonza). Cells were always grown to 
near confluence before experimental use. 
Cell treatments
The SNB-19 and UP007 cells were first serum-
starved for 24h, then incubated with BGB324 (gift of 
BergenBio, Bergen, Norway) at the concentrations and 
times indicated, in the absence or presence of recombinant 
human Gas6 protein (400 ng/ml) (R&D Systems, 
Abingdon, UK). In experiments using recombinant human 
epidermal growth factor (EGF; R&D Systems), cells 
were incubated with 50 ng/ml of EGF for 15min to cause 
activation of EGFR, whilst in inhibition experiments, 
cells were pre-incubated with 10 µM gefitinib (EGFR 
SMI; Santa Cruz Biotechnology, Santa Cruz, CA) for 2h 
prior to EGF stimulation. In experiments using TMZ, cells 
were incubated with 10 μM, 25 μM and 50 μM alone or in 
combination with BGB324 for 3 days.
RNA extraction and quantitative real-time 
polymerase chain reaction
Cellular total RNA was isolated using GeneJET 
RNA purification kit (Life Technologies) according 
to the manufacturer’s protocol. First-strand cDNA 
was synthesized using the nanoScript reverse 
transcription kit (Primer Design, Southampton, 
UK). Quantitative PCR (qPCR) amplification was 
performed in 96-well plates in a mastermix for probes 
(Roche, Burgess Hill, UK) and run on a LightCycler® 
96 System (Roche). The qPCR amplifications for 
the human AXL (assay I.D. Hs.PT.56a.1942285), 
MERTK (assay I.D. Hs.PT.58.2640315), TYRO3 
(assay I.D. Hs.PT.58.38778546) and GAS6 (assay 
I.D. Hs.PT.58.21535693) genes were performed 
using pre-designed primers/probes purchased from 
Integrated DNA Technologies (Leuven, Belgium). The 
amplification procedure entailed 45 cycles of 95oC for 
10sec followed by 60oC for 30sec. Relative expression 
analysis was performed using the equation N = N0 x 2
Cp 
(LightCycler®96 software; Roche), normalising against 
the gene for ATP synthase subunit beta (ATP5B), which 
was determined in-house as the best internal reference 
gene out of 12 genes tested (geNorm kit, Primerdesign, 
Southampton, UK; data not shown). 
Immunohistochemistry
Brain tumour tissue array sections on glass slides, 
with normal tissue as control (GL805a; US Biomax, 
Rockville, MD) were deparaffinised using histology 
grade xylene (Sigma-Aldrich, Dorset, UK) for 5min and 
rehydrated using descending concentrations (100%, 70%, 
50%, 30%) of molecular grade ethanol (Fisher Scientific) 
for 1min and 30sec respectively. Slides were then rinsed 
for 2min in water. Antigen unmasking was performed 
in 0.01 M sodium citrate (Fisher Scientific), pH 6 at 
95oC with two changes for 5min each. The slides were 
washed twice for 2mins in deionized water. Endogenous 
peroxidase activity was blocked by incubating with 0.1% 
hydrogen peroxide (Sigma-Aldrich) at room temperature. 
Following three 5min washes with Phosphatase Buffered 
Saline (PBS), the slides were blocked with 1.5% rabbit 
serum in PBS for 1h. The test slide was then incubated 
with anti-Axl antibody at 1:100 dilution (goat polyclonal; 
R&D Systems) in 1.5% rabbit serum/PBS for 2h. The 
slides were then washed with PBS 3 times for 5min and 
incubated with biotinylated anti-goat IgG secondary 
antibody (Sigma-Aldrich) in 1.5% rabbit serum/PBS for 
1h at room temperature. The slides were then incubated for 
30 min with avidin-biotin enzyme reagent VECTASTAIN 
ABC Kit (Vector laboratories, Peterborough, UK) and 
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washed with PBS three times for 5min. The slides were 
then developed using ImmPACT DAB Peroxidase (HRP) 
Substrate (Vector laboratories) for 10sec and washed 
with deionizing water three times for 5min. The tissues 
were counter-stained with haematoxylin and dehydrated 
through increasing concentrations of alcohols (50%, 70% 
95% 100%) for 30sec and 1min respectively, followed 
by xylene for 1min, after which they were mounted with 
DPX (Sigma-Aldrich). Images were captured by a Zeiss 
Axiophot brightfield microscope at 20x magnification. 
Western blotting
Cells were briefly rinsed in ice-cold phosphate-
buffered saline (PBS; Fisher Scientific) and lysed in 
ice-cold RIPA lysis buffer (150 mM NaCl, 1% Triton 
X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM 
Tris pH 8.0) supplemented with a cocktail of protease 
and phosphatase inhibitors (Fisher Scientific). Cell 
lysates were clarified by centrifugation and the proteins 
electrophoretically separated by 10% SDS polyacrylamide 
gel electrophoresis (SDS-PAGE). Cell lysates were also 
prepared from primary human brain microvascular 
endothelial cells (hCMEC/D3) and primary human 
cerebellar astrocytes (HA-c) (ScienCell, Carlsbad, 
CA). The separated proteins were transferred by a wet 
transfer method onto an activated polyvinylidene fluoride 
membrane (Millipore, Nottingham, UK). Membranes 
were incubated for 1h at room temperature in blocking 
buffer, which was either Tris-buffered saline-Tween 0.1% 
(TBS-T; Fisher Scientific) containing 3% non-fat dry milk, 
or otherwise containing 3% bovine serum albumin (BSA; 
Fisher Scientific) if probing for phosphorylated proteins. 
After blocking, membranes were incubated with primary 
antibody diluted in appropriate blocking buffer overnight 
at 4°C, then washed (3 x 5min) with TBS-T and incubated 
with appropriate horseradish peroxidase (HRP)-conjugated 
secondary antibody diluted in appropriate blocking buffer 
for 1h at room temperature. Following washing with 
TBS-T (3 x 5min), membranes were incubated with an 
enhanced chemiluminescence development reagent 
(Luminata Forte; Millipore) for 3min and visualised with a 
high sensitivity CCD camera imaging platform (Chemidoc 
MP; Bio-Rad, Hemel Hempstead, UK). The software 
ImageJ [36] was used for densitometric quantification of 
western blot band intensities. 
The primary antibodies (and dilutions) used were: 
Axl (C-20) (goat polyclonal; 1:1,000), Tyro3 (C-20) (goat 
polyclonal; 1:1,000), MerTK (B-1) (mouse monoclonal; 
1:1,000), p-EGFR and EGFR (goat polyclonal; 1:1,000) 
(Santa Cruz), p-Axl (rabbit polyclonal; 1:500; R&D 
systems), p-Akt 1/2/3 and Akt 1/2/3 (rabbit polyclonal; 
1:1,000; Santa Cruz), p-Sky/Mer (rabbit polyclonal; 
1:1,000), β-Actin (rabbit polyclonal; 1:5,000) (Sigma, 
Poole, UK). Secondary antibodies used were donkey anti-
rabbit HRP (1:2,000; Dako, Cambridge, UK), anti-goat 
HRP (1:5,000) and anti-mouse HRP (1:5,000) (Promega, 
Southampton, UK). 
Cell survival/growth assay
1,500 cells per well were seeded in 96-well plates 
and incubated overnight, prior to various treatments 
(see above). Three or seven days post drug or Gas6 
treatment respectively, 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxy-phenyl)-2-(4-sulfo-phenyl)-
2H-tetrazolium (MTS) (Fisher Scientific) was added 
to cells at 0.4 µM in the presence of 0.3 nM phenazine 
methosulfate (Sigma) and incubated for a further 2h, 
after which absorbance was measured at 492 nm using a 
spectrophotometric microplate reader (Synergy; BioTek, 
Potton, UK). 
Apoptosis assay
30,000 cells per sample were treated with 2.5 µM 
and 5 µM (SNB-19) or 1 µM and 2 µM BGB324 (UP007) 
or vehicle (DMSO) for 24h. Following drug treatments the 
cells were centrifuged at 400 x g for 5min and resuspended 
in Annexin V binding buffer and incubated with Annexin 
V-CF488A conjugate and Hoechst 33342 (Insight 
Biotechnology, Wembley, UK) for 15min at 37oC using a 
heating block. The cells were then spun down at 400 x g 
for 5min and washed with Annexin V binding buffer twice 
by repeating the centrifugation and resuspension. Finally 
the cells were resuspended in 100 µl supplemented with 10 
µg/ml propidium iodide (Insight Biotechnology) and 30 µl 
was loaded onto a special chamber slide (NC-Slide A2™) 
and cell populations were analysed for Annexin V/PI 
fluorescence (NucleoCounter® NC-3000™; Chemometec 
A/S, Allerød, Denmark) according to the manufacturer’s 
protocol. 
Scratch wound assay
Linear cell migration along a surface was measured 
by scratch wound assay, where a linear scratch was made 
in a confluent cell monolayer with a 200 µl yellow pipette 
tip. Following injury, wound closure was monitored using 
an inverted Zeiss Axiovert 200M microscope housed in 
a live cell imaging chamber under normal cell culture 
conditions (37°C, 5% CO2, humid atmosphere). Images 
of 4 points per well were captured every 3h over a total 
period of 21h. Image analysis following the experiment 
was performed using ImageJ, and cell migration rates 
(area change/h) calculated thereafter. 
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Cell motility assay
GBM cells were seeded in 24-well plates at low 
density (1,500 cells/well). Following treatment with 
BGB324 or vehicle (DMSO), live cell microscopic 
images of 4 points per well were taken every 20min 
for 24h under normal culture conditions (37°C, 5% 
CO2, humid atmosphere) using a Zeiss Axiovert 200M 
inverted live cell microscope with time-lapse imaging 
at 10x magnification. Quantification of cell tracking, 
measuring distance and trajectory were performed using 
ImageJ with its Cell Tracking plug-in. In total, 60 cells 
per condition were tracked randomly for a period of 3h, 
with total distance (µm) and average velocity (µm/min) 
being calculated. 
Colony growth assay
Wells of 24-well plates were first coated with 0.5 
mL of complete medium/0.5% agar, and then GBM cells 
suspended in complete medium/0.35% agar were seeded 
at low density (1,500 cells/well). Cells were incubated 
for 2 weeks in total, with media and treatments being 
replenished weekly. Colonies present at the end of 
the incubation period were stained by incubation with 
0.05% crystal violet solution (Fisher Scientific) for 1h. 
Images were taken of each well using a Zeiss Stemi SVG 
dissecting microscope (1.5 x magnification), and colonies 
were counted in 5 different fields of view. 
Cell invasion assay
Modified Boyden transwell chambers were used to 
assess cell invasion through extracellular matrix. Briefly, 
polycarbonate hanging inserts (Corning, Amsterdam, The 
Netherlands) were coated with 60 µg/ml Geltrex™ LDEV-
free reduced growth factor basement membrane matrix 
(Life Technologies). Invasion in the cell culture incubator 
was allowed to occur over 6h for UP007 cells (20,000 
cells/well) and 16h for SNB-19 cells (10,000 cells/well). 
Non-invading cells on the upper surface of the filter were 
removed with a cotton swab and cells that had invaded 
and adhered to the lower side of the filter were fixed for 
15min with 37% formaldehyde solution containing 10-
15% methanol (Sigma). Following fixation and brief 
wash with PBS, the adherent cells were stained with 0.5% 
crystal violet. Images were captured by a Zeiss Axiophot 
brightfield microscope and cells were counted in 5 random 
fields at a 10x magnification. Invasion was expressed as 
mean fold ± standard error of the mean (SEM) of the 
number of total cells counted per well. 
Statistical analyses
All data are expressed as mean±SEM, obtained 
from a minimum of 3 independent experiments, each 
constituting multiple replicates per condition. Quantitative 
data were analysed by Analysis of Variance (ANOVA) 
with post-hoc Bonferroni test for multiple comparisons 
with one control group “or multiple time points/treatments, 
or paired t-test for comparisons of control with treatment 
“ Statistical analyses and graphical representations were 
performed using Prism (GraphPad Software Inc). The 
level of statistical significance is indicated in the figures 
and accompanying legends. Western blot image processing 
was performed using Adobe Photoshop CC 2014 software 
(Adobe Systems Incorporated, CA, USA). 
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